NeurogesX, Inc. (NGSX)
-OTC Markets 0.01 
0.00(10.00%) 3:39PM EDT|After Hours
:
0.28 0.00 (0.00%) 4:13PM EDT - Nasdaq Real Time Price
| Prev Close: | 0.01 |
|---|
| Open: | 0.01 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.01 - 0.02 |
|---|
| 52wk Range: | 0.01 - 0.41 |
|---|
| Volume: | 13,390 |
|---|
| Avg Vol (3m): | 250,632 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NEUROGESX INC FinancialsEDGAR Online Financials(Thu May 23)
- NEUROGESX INC FinancialsEDGAR Online Financials(Wed Apr 24)
- NEUROGESX INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Wed Apr 17)
- Pain patch developer NeurogesX cans 8 of 11 employees, looks for buyerat bizjournals.com(Fri Mar 8)
- NeurogesX to cut 9 jobsat bizjournals.com(Fri Nov 30)
- The Funded: Versa Networks, NeurogesX, Nanosys, Aggregate Knowledgeat bizjournals.com(Mon Nov 26)
- 3 Best Biotech Stocks For This Week (Part V)at Seeking Alpha(Mon Oct 8)
- NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcriptat Seeking Alpha(Mon Aug 6)
- NeurogesX receives additional notice of allowance covering NGX-1998 in U.S.theflyonthewall.com(Thu Aug 2)
- NeurogesX announces enrollment of first patient in its ELEVATE clinical trialat theflyonthewall.com(Tue Jul 24)
- NeurogesX receives notice of two U.S. Patent allowances covering NGX-1998theflyonthewall.com(Tue Jun 19)
- NeurogesX issued Japanese patent for NGX-1998at theflyonthewall.com(Mon Jun 18)
- NEUROGESX INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue Nov 8)
- NEUROGESX INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue Nov 8)
- NEUROGESX INC Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated with Exit or DisposEDGAR Online(Mon Oct 31)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NeurogesX, Inc., a biopharmaceutical company, engages in developing and commercializing pain management therapies. The company offers Qutenza for the management of neuropathic pain associated with postherpetic neuralgia, and for the treatment of p...
View More